Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 5:29 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 7,451 matching trials from the live ClinicalTrials.gov search.
Filters: Denver, Colorado Clear all
Completed Not applicable Interventional Results available

A Study to Evaluate the Safety and Effectiveness of a Contact Lens Cleaning and Disinfecting Solution

NCT05565937
View directory record Official record
Conditions
Refractive Ametropia
Interventions
BL-3100-NBR03 multi-purpose solution, renu® Advanced Formula multi-purpose solution
Device
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
19
States / cities
San Diego, California • San Francisco, California • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated May 20, 2025 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Bay1002670, Fibroids, Safety and Efficacy EU,US,Can, Jap

NCT02131662
View directory record Official record
Conditions
Leiomyoma
Interventions
BAY1002670, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
36
States / cities
Mesa, Arizona • Tucson, Arizona • San Diego, California + 29 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2017 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

Study Comparing Combination of LGX818 Plus MEK162 Versus Vemurafenib and LGX818 Monotherapy in BRAF Mutant Melanoma

NCT01909453
View directory record Official record
Conditions
Melanoma
Interventions
LGX818, MEK162, vemurafenib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2024
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Not applicable Interventional

rEEG Guided Pharmacotherapy of Subjects With Depression Treatment Failure

NCT00437827
View directory record Official record
Conditions
Depressive Disorder
Interventions
Star*D algorithm, rEEG-guided therapy
Other
Lead sponsor
MYnd Analytics
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
13
States / cities
Glendale, California • Irvine, California • San Bernardino, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2009 · Synced Oct 31, 2026, 5:29 PM EDT
Terminated Phase 3 Interventional Results available

Phase III Acute Coronary Syndrome

NCT00831441
View directory record Official record
Conditions
Acute Coronary Syndrome
Interventions
Apixaban, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
7,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
221
States / cities
Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 179 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2016 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

A Placebo Controlled Trial Of L-Tryptophan In Post-Operative Delirium

NCT00865202
View directory record Official record
Conditions
Post-operative Delirium
Interventions
L-tryptophan supplementation, placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 1, 2017 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Development and Health of Rural Chinese Children Fed Meat as a Daily Complementary Food From 6-18 Mos of Age

NCT00726102
View directory record Official record
Conditions
Nutritional Deficiencies
Interventions
Meat, Cereal, fortified rice cereal
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Months to 18 Months
Enrollment
1,488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 31, 2026, 5:29 PM EDT
Active, not recruiting Phase 1 Interventional

Study of PYX-106 in Solid Tumors

NCT05718557
View directory record Official record
Conditions
Solid Tumor
Interventions
PYX-106
Drug
Lead sponsor
Pyxis Oncology, Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 31, 2026, 5:29 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer

NCT05608044
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Botensilimab, Balstilimab, Standard of Care
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
26
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)

NCT02216214
View directory record Official record
Conditions
Overactive Bladder (OAB)
Interventions
Mirabegron, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
65 Years and older
Enrollment
888 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
103
States / cities
Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 88 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2024 · Synced Oct 31, 2026, 5:29 PM EDT
Not listed Phase 2 Interventional

Dose-Finding Study of REN-1654 in Patients With Post-Herpetic Neuralgia

NCT00099528
View directory record Official record
Conditions
Neuralgia, Shingles, Peripheral Nervous System Disease
Interventions
REN-1654
Drug
Lead sponsor
Renovis
Industry
Eligibility
55 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
16
States / cities
Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2010 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

ACCESS: A Controlled Comparison of Eritoran Tetrasodium and Placebo in Patients With Severe Sepsis

NCT00334828
View directory record Official record
Conditions
Severe Sepsis
Interventions
eritoran tetrasodium, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
69
States / cities
Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study Designed to Assess the Safety, Tolerability and PK of PTI-808 in Healthy Volunteers and in Adults With Cystic Fibrosis

NCT03251092
View directory record Official record
Conditions
Healthy Volunteer - Complete, Cystic Fibrosis - Complete
Interventions
PTI-808, Placebo, PTI-428, PTI-801
Drug
Lead sponsor
Proteostasis Therapeutics, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
179 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
22
States / cities
Tucson, Arizona • Stanford, California • Denver, Colorado + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2020 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy

NCT02366871
View directory record Official record
Conditions
Gynecologic Cancer, Venous Thromboembolism
Interventions
Oral apixaban, Subcutaneous enoxaparin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 89 Years · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Los Angeles, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional

Study to Evaluate the Safety of Twice Daily Oral Carvedilol

NCT00129363
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
Carvedilol
Drug
Lead sponsor
Shaddy, Robert, M.D.
Individual
Eligibility
1 Day to 17 Years
Enrollment
75 participants
Timeline
2002 – 2006
U.S. locations
17
States / cities
Los Angeles, California • Palo Alto, California • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Dec 25, 2008 · Synced Oct 31, 2026, 5:29 PM EDT
Completed No phase listed Observational

Study to Determine the Relationship Between Exercise and Hypoglycemia in Children With Type 1 Diabetes

NCT00109434
View directory record Official record
Conditions
Diabetes Mellitus, Type I
Interventions
Not listed
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
10 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004
U.S. locations
5
States / cities
Stanford, California • Denver, Colorado • New Haven, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2016 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib With Either Temsirolimus or Tipifarnib in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed By Surgery

NCT00281957
View directory record Official record
Conditions
Recurrent Melanoma, Stage IV Melanoma
Interventions
sorafenib tosylate, tipifarnib, temsirolimus
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
173
States / cities
Little Rock, Arkansas • Castro Valley, California • Fremont, California + 113 more
Source: ClinicalTrials.gov public record
Updated May 20, 2014 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Not applicable Interventional Results available

Day and Night Closed-loop in Young People With Type 1 Diabetes

NCT02925299
View directory record Official record
Conditions
Diabetes Mellitus, Diabetes Mellitus, Type 1, Glucose Metabolism Disorders, Endocrine System Diseases, Autoimmune Diseases
Interventions
FlorenceM (US) and FlorenceX (UK), Insulin pump therapy
Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
6 Years to 18 Years
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
5
States / cities
Palo Alto, California • Aurora, Colorado • Hartford, Connecticut + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Not applicable Interventional Results available

Telecommunication Enhanced Asthma Management

NCT00958932
View directory record Official record
Conditions
Asthma
Interventions
Speech recognition
Behavioral
Lead sponsor
National Jewish Health
Other
Eligibility
3 Years to 12 Years
Enrollment
1,187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 31, 2026, 5:29 PM EDT
Recruiting Phase 3 Interventional

Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer

NCT06958328
View directory record Official record
Conditions
Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Capecitabine, Computed Tomography, Dose-escalated Radiation Therapy, Fluorouracil, Gemcitabine, Irinotecan Hydrochloride, Irinotecan Sucrosofate, Leucovorin Calcium, Magnetic Resonance Imaging, Nab-paclitaxel, Observation Activity, Oxaliplatin, Positron Emission Tomography, Questionnaire Administration, Radiation Therapy, Tumor Treating Fields Therapy
Procedure · Drug · Radiation + 1 more
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
332
States / cities
Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 252 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Active, not recruiting Phase 3 Interventional

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)

NCT05263934
View directory record Official record
Conditions
Eosinophilic Granulomatosis With Polyangiitis
Interventions
Depemokimab, Mepolizumab, Placebo matching mepolizumab, Placebo matching depemokimab
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
6
States / cities
Denver, Colorado • Gainesville, Florida • Rochester, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 31, 2026, 5:29 PM EDT
Completed No phase listed Observational

Validation of Lower Body Negative Pressure (LBNP) Model of Human Hemorrhage in Trauma Patients

NCT01871909
View directory record Official record
Conditions
Physical Trauma
Interventions
Not listed
Lead sponsor
University of Colorado, Denver
Other
Eligibility
31 Days to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
3
States / cities
Aurora, Colorado • Denver, Colorado • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Not applicable Interventional

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

NCT00023387
View directory record Official record
Conditions
Tuberculosis
Interventions
Rifapentine, 25-desacetyl Rifapentine, Isoniazid
Drug
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2001
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2005 · Synced Oct 31, 2026, 5:29 PM EDT
Completed Phase 3 Interventional Results available

A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis

NCT02696798
View directory record Official record
Conditions
Spondyloarthritis
Interventions
Ixekizumab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
27
States / cities
Phoenix, Arizona • Escondido, California • Huntington Beach, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2020 · Synced Oct 31, 2026, 5:29 PM EDT